<DOC>
	<DOCNO>NCT00956176</DOCNO>
	<brief_summary>The goal clinical research study learn body absorbs process 1 dose cidofovir give directly bladder , patient viral infection cause bleed bladder . The safety drug dose investigational way give ( directly bladder ) also study .</brief_summary>
	<brief_title>Cidofovir Instillation Hematopoietic Stem Cell Transplant ( HSCT ) Recipients With Hemorrhagic Cystitis</brief_title>
	<detailed_description>The Study Drug : Cidofovir design fight CMV ( viral infection ) block CMV cell divide . Cidofovir commonly give injection . For research purpose , study give directly bladder foley catheter . This one first study cidofovir give way human . Study Drug Administration : If find eligible take part study , Day 1 , Cidofovir put bladder foley catheter . The catheter clamp 2 hour keep drug bladder . After 2 hour , catheter unclamped . If receive bladder irrigation therapy hemorrhagic cystitis , restart . Study Tests Day 1 : On day receive cidofovir , blood ( 2 teaspoon ) draw 6 time . The first blood draw occur cidofovir dose , last blood draw occur 24 hour ( +/- 1 hour ) start dose . This blood use pharmacokinetic ( PK ) pharmacodynamic ( PD ) test . PK test measure amount study drug body different time point . PD test use look level study drug body may affect disease . Viral Load Testing : During study , extra urine leftover blood collect used research test certain virus . These virus include type infection joining study , well cytomegalovirus ( CMV ) another type herpes virus . The urine sample collect cidofovir dose Day 1 , cidofovir dose Day 1 , Day 4 . Any blood leave Day 1 test also use viral load test . It possible urine and/or blood sample send outside lab perform testing . If occurs , name personal identifying information cod sample send . Coding sample design protect privacy . Follow-Up Tests : Blood ( 2 teaspoon ) draw routine test 2 time week cidofovir dose . On Day 7 ( +/- 2 day ) , check side effect could relate study drug . In addition , Day 14 ( +/- 2 day ) , blood sample draw PK testing , urine collect routine test , safety data record . One final follow-up visit take place Day 30 ( +/- 2 day ) . During visit , study staff record serious side effect may experience . Length Study Participation : Your active study participation Day 7 follow-up visit ( +/- 2 day ) . If experienced side effect , however , study staff continue check medical record side effect become stable get well . This investigational study . Cidofovir give injection commercially available FDA approve treat CMV patient HIV . It investigational give cidofovir directly bladder patient viral infection cause bleed bladder . Up 6 patient take part study . All enrol M. D. Anderson .</detailed_description>
	<mesh_term>Cystitis</mesh_term>
	<mesh_term>Urinary Bladder Diseases</mesh_term>
	<mesh_term>Cidofovir</mesh_term>
	<criteria>1 . Polyoma BK adenovirus viruria establish either positive urine cytology PCR BK virus positive urine and/or blood culture adenovirus 2 . The patient either gross hematuria and/or pass blood clot 3 . Signed informed consent form 4 . Hospitalized patient Foley catheter 5 . Women childbearing potential must agree use 2 acceptable method birth control ( e. g. , abstinence , IUD , barrier method ) , study period one period 2 month afterward . At least one method must barrier method . Males must also agree use acceptable method birth control ( barrier method ) study period 2 month afterward . 1 . Serum creatinine &gt; 1.5 mg/dl and/or calculate creatinine clearance &lt; 55 ml/min use CockcroftGault Creatinine Clearance formula ( CrCl ) . CrCl = { ( 140Age ) x Weight ( kg ) x 0.85 ( female ) } / { 72x Serum Creatinine ( mg/dl ) } 2 . Urine protein &gt; 100 mg/dl ( equivalent &gt; 2+ proteinuria ) 3 . Age le 18 year 4 . Prior therapy formalin carboprost 1 mg % administer intravesically 5 . Hypersensitivity cidofovir , probenecid sulfacontaining medication 6 . Have receive prior cidofovir therapy within 2 week . 7 . Prior enrollment study 8 . Women pregnant breastfeed 9 . Evidence endorgan adenoviral infection</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2012</verification_date>
	<keyword>Cidofovir</keyword>
	<keyword>Vistide</keyword>
	<keyword>Adenovirus</keyword>
	<keyword>BK virus infection</keyword>
	<keyword>HSCT</keyword>
	<keyword>Hemorrhagic Cystitis</keyword>
	<keyword>Foley catheter</keyword>
	<keyword>Viral infection</keyword>
	<keyword>Bladder instillation</keyword>
	<keyword>Intravesical</keyword>
	<keyword>Transurethral catheter</keyword>
	<keyword>Transplantation</keyword>
</DOC>